CURRICULUM VITAE

09/29/2014

I. PERSONAL Izidore Lossos, MD Professor of Medicine Director, Lymphoma Program University of Miami Division of Hematology-Oncology Office: (305) 243-4785 Fax: (305) 243-4787 II. HIGHER EDUCATION Institutional Hadassah Medical School,Hebrew University,

Jerusalem, Israel –M.D. - 2/1987 Certifications ECFMG No. 403-820-4 – 1988

Israeli Board Certification, Internal Medicine –

1994, permanent Israeli Board Certification, Hematology –1997,

permanent III. EXPERIENCE Academic Hebrew University, Jerusalem, Israel; Instructor in Internal Medicine, 5/1993-4/1996

Hebrew University, Jerusalem, Israel; Assistant Professor in Hematology and Internal Medicine, 5/1996-8/2000 University of Miami, FL; Associate Professor of Clinical Medicine, 9/2002-5/2005 University of Miami, FL Associate Professor of Molecular and Cellular Pharmacology, 3/2003-5/2008

1

University of Miami, FL; Associate Professor of Medicine, 6/2005-5/2008 University of Miami, FL; Professor of Medicine 5/2008- present University of Miami, FL Professor of Molecular and Cellular Pharmacology, 5/2008- present

Non-Academic Department of Internal Medicine, Hadassah

University Hospital, Mount Scopus, Jerusalem. Israel; Residency, 5/1991-4/1995

Department of Hematology, Hadassah

University Hospital, Jerusalem, Israel; Fellowship, 5/1995-11/1997

Department of Medicine, Division of Oncology,

Stanford University Medical Center, Stanford, CA; Post Doctoral Fellowship, 8/1998-7/2001

Department of Medicine, Division of Oncology,

Stanford University Medical Center, Stanford, CA; Senior Research Associate, 8/2001-8/2002

Hospital Appointments Jackson Memorial Hospital, Attending Physician 2002 – present

University of Miami Hospital and Clinics, Attending Physician 2002 – present

Director-Lymphoma Program 2006- present

Endowed Chair of Lymphoma, Sylvester

Comprehensive Cancer Center 2008 – present

2

Military IDF Army, Major, Division Physician and Head of Millitary Clinic/Hospital; 2/1987-4/1991

3

IV. PUBLICATIONS Books and Monographs

1. Lossos IS, Alencar AJ. MicroRNAs in Diffuse Large B-Cell Lymphoma. In:

MicroRNAs in Medicine, First Edition. Edited by Charles H. Lawrie. John

Wiley & Sons; 2014:419-433.

2. Lossos IS. Developing prognostic models for diffuse large B-cell

lymphoma. In: Jones D. Neoplastic Hematopathology. Experimental and

clinical approaches. Humana Press, London. 2010:553-562.

3. Tsao L, Hsi ED, Lossos IS. Pathology and pathogenesis of post-transplant

Lymphoproliferative disorders. In: Ruiz P. Transplantation Pathology.

Cambridge University Press; 2009: 351-368.

4. Lossos IS, Morgensztern D. Prognostic factors in diffuse large B-cell

lymphoma: present and future. Am Soc Clin Oncol Ed Book 2007:496-

501.

5. Zelenetz AD, Lossos IS, Moskowitz CH. Towards a strategy for risk

adapted therapy in DLBCL. Am Soc Clin Oncol Ed Book 2007: 507-509.

6. Breuer R, Lossos I, Epler G. Bone marrow transplantation - related

pulmonary complications. ACCP 7: Pulmonary and critical care update.

Illinois; 1992:1-9.

7. Breuer R, Lossos I, Epler G. Pulmonary complications in bone-marrow

transplantation. In: Fishman A, ed. Update: pulmonary diseases and

disorders. McGraw-Hill Co; 1992:115-124.

Juried or Refereed Journal Articles (underlined names depicts equal contribution)

1. Mendez V, Martinez FJ, Soriano FB, Markoe AM, Lossos IS, Saigal K,

Sussman DA. Novel use of endoscopic clips as fiducials for radiotherapy

4

in small bowel lymphoma. ACG Case Reports Journal. 2014 July 1;4:184-

6.

2. Green MR, Vicente-Duenas C, Romero-Camarero I, Long Liu C, Dai B,

Gonzalez-Herrero I, Garcia-Ramirez I, Alonso-Escudero E, Iqbal J, Chan

WC, Campos-Sanchez E, Orfao A, Pintado B, flores, T, Blanco O,

Jimenez R, Martinez-Climent JA, Criado FJ, Cenador MB, Zhao S,

Natkunam Y, Lossos IS, Majeti R, Melnick A, Cobaleda C, Alizadeh AA,

Sanchez-Garcia I. Transient expression of Bcl6 is sufficient for oncogenic

function and induction of mature B-cell lymphoma. Nature

Communications. 2014 Jun 2;5:3904.

3. Chapman-Fredricks J, Sandoval-Sus J, Vega F, Lossos IS. Progressive

leukemic non-nodal mantle cell lymphoma associated with deletions of

TP53, ATM, and / or 13q14. Annals of Diagnostic Pathology. 2014 Aug;

18(4):214-9. Epub 2014 Apr 13.

4. Sandoval-Sus JD, Sandoval-Leon AC, Chapman JR, Velazquez-Vega J,

Borja MJ, Rosenberg S, Lossos A, Lossos IS. Rosai-Dorfman disease of

the central nervous system: report of six cases and review of the literature.

Medicine (Baltimore). 2014 Mar;93(3):165-75.

5. Evens AM, Smith MR, Lossos IS, Helenowski I, Millenson M, Winter JN,

Rosen ST, Gordon LI. Frontline bortezomib and rituximab for the

treatment of newly diagnosed high tumor burden indolent non-hodgkin

lymphoma: a multicenter phase II study. British Journal of Haematology.

2014 Aug;166(4):514-20 Epub 2014 Apr 25.

6. Lossos C, Bayraktar S, Weinzierl E, Younes SF, Hosein PJ, Tibshirani RJ,

Sutton Posthumus J, DeAngelis LM, Raizer J, Schiff D, Abrey L,

Natkunam Y, Lossos IS. LMO2 and BCL6 are associated with improved

survival in primary central nervous system lymphoma. British Journal of

Haematology. 2014 Jun; 165(5):640-8. Epub 2014 Feb 26.

7. Hosein PJ, Maragulia JC, Salzberg MP, Press OW, Habermann TM, Vose

JM, Bast M, Advani RH, Tibshirani R, Evens AM, Islam N, Leonard JP,

Martin P, Zelenetz A, Lossos IS. A multicentre study of primary breast

5

diffuse large B-cell lymphoma in the rituximab era. British Journal of

Haematology. 2014 May; 165(3):358-63. Epub 2014 Jan 27.

8. Palomero T, Couronné L, Khiabanian H, Kim MY, Ambesi-Impiombato A,

Perez-Garcia A, Carpenter Z, Abate F, Allegretta M, Haydu JE, Jiang X,

Lossos IS, Nicolas C, Balbin M, Bastard C, Bhagat G, Piris MA, Campo E,

Bernard OA, Rabadan R, Ferrando AA. Recurrent mutations in epigenetic

regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nature

Genetics. 2014 Feb 46;(2):166-70. Epub 2014 Jan 12.

9. Friedberg JW, Mahadevan D, Cebula E, Persky D, Lossos I, Agarwal AB,

Jung J, Burack R, Zhou X, Leonard EJ, Fingert H, Danaee H, Bernstein

SH. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in

relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.

Journal of Clinical Oncology. 2014 Jan 1;32(1)44-50. Epub 2013 Sep 16.

10. Evens Am, Advani R, Press OW, Lossos IS, Vose JM, Hernandez-

Ilizaliturri FJ, Robinson BK, Otis S, Nadav Dagan LO, Abdallah R, Kroll-

Desrosiers A, Yarber JL, Sandoval J, Foyil K, Parker LM, Gordon LI, Blum

KA, Floowers CR, Leonard JP, Habermann TM, Bartlett NL. Lymphoma

occuring during pregnancy: antenatal therapy, complications, and

maternal survival in a multicenter analysis. Journal of Clinical Oncology.

2013 Nov 10;31(32):4132-9. Epub 2013 Sep 16.

11. Bhatt S, Ashlock BM, Natkunam Y, Sujoy V, Chapman JR, Ramos JC,

Mesri EA, Lossos IS. CD30 targeting with brentuximab vedotin – a novel

therapeutic approach to primary effusion lymphoma. Blood. 2013 Aug

15;122(7):1233-42. Epub 2013 Jul 9.

12. Vose JM, Habermann TM, Czuczman MS, Zinzani PL, Reeder CB,

Tuscano JM, Lossos IS, Li J, Pietronigro D, Witzig TE. Single-agent

lenalidomide is active in patients with relapsed or refractory aggressive

non-Hodgkin lymphoma who received prior stem cell transplantation.

British Journal of Haematology. 2013 Sep;162(5):639-47. Epub 2013 Jul

9.

6

13. Bertolo C, Roa S, Sagardoy A, Mena-Varas M, Robles EF, Martinez-

Ferrandis JI, Sagaert X, Tousseyn T, Orta A, Lossos IS, Amar S,

Natkunam Y, Briones J, Melnick A, Malumbres R, Martinez-Climent JA.

LITAF, a BCL6 gene, regulates autophagy in mature B-cell lymphomas.

British Journal of Haematology. 2013 Sep;162(5):621-30. Epub 2013 Jun

25.

14. Zhu D, Ikpatt OF, Dubovy SR, Lossos C, Natkunam Y, Chapman-

Fredricks JR, Fan Y, Lossos IS. Molecular and genomic aberrations in

Chlamydophila psittaci negative ocular adnexal marginal zone

lymphomas. American Journal of Hematology. 2013 Sep;88(9):730-5.

Epub 2013 Jul 23.

15. Tinoco G, Kanji R, Lossos IS, Hosein PJ. Acute Reversible tetraplegia

Induced by Hyperkalemia in a Patient with Paravertebral Mass due to

Lymphoma. Journal of Clinical Case Reports. 2013; 3:4.

16. Matasar MJ, Czuczman MS, Rodriguez MA, Fennessy M, Shea TC,

Spitzer G, Lossos IS, Kharfan-Dabaja MA, Joyce R, Fayad L, Henkel K,

Liao Q, Edvardsen K, Jewell RC, Fecteau D, Singh RP, Lisby S,

Moskowitz CH. Ofatumumab in combination with ICE or DHAP

chemotherapy in relapsed or refractory intermediate grade B-cell

lymphoma. Blood. July 25; 122(4):499-506. Epub 2013 May 21.

17. Bhatt S, Ashlock BM, Toomey NL, Diaz LA, Mesri EA, Lossos IS, Ramos

JC. Efficacious proteasome/HDAC inhibitor combination therapy for

primary effusion lymphoma. Journal of Clinical Investigation. 2013 Jun 3;

123(6):2616-2628. Epub 2013 May 1.

18. Campuzano-Zuluaga G, Cioffi-Lavina M, Lossos IS, Chapman-Fredricks

JR. Frequency and Extent of CD30 Expression in Diffuse Large B-Cell

Lymphoma and its Relation to Clinical and Biologic Factors: A

retrospective study of 167 cases. Leukemia Lymphoma. 2013 Nov;

54(11)2405-11. Epub 2013 April 4.

19. Zhu D, Lossos C, Chapman-Fredricks JR, Lossos IS. Biased

Immunoglobulin Light Chain Use in the Chlamydophila psittaci Negative

7

Ocular Adnexal Marginal Zone Lymphomas. American Journal of

Hematology. 2013 May;88(5):379-384. Epub 2013 March 28.

20. Romero-Camarero I, Jiang X, Natkunam Y, Lu X, Vicente-Duenas C,

Gonzalez-Herrero I, Flores T, Garcia JL, McNamara G, Kunder C, Zhao S,

Segura V, Fontan L, Martinez-Climent JA, Garcia-Criado FJ, Theis JD,

Dogan A, Campos-Sanchez E, Green MR, Alizadeh AA, Cobaleda C,

Sanchez-Garcia I, Lossos IS. Germinal centre protein HGAL promotes

lymphoid hyperplasia and amyloidosis via BCR-mediated Syk activation.

Nature Communications. 2013 Jan 8; 4:1338.

21. Chapman-Fredricks J, Younes SF, Fan YS, Sandoval-Sus JD, Natkunam

Y, Lossos IS. Usefulness of HGAL and LMO2 immunohistochemistry in

the identification of follicular lymphomas of the non-gastric gastrointestinal

tract. Applied Immunohistochemistry & Molecular Morpholology. 2013

May;21(3):200-204.

22. Vincente-Duenas C, Romero-Camarero I, Gonzalez-Herrero I, Alonso-

Escudero E, Abollo-Jimenez F, Jiang X, Gitierrez NC, Orfao A, Marin N,

Villar LM, Fernandez Criado C, Pintado B, Flores T, Alonso-Lopez D, De

Las Rivas J, Jimenez R, Garcia Criado FJ, Garcia Cenador MB, Lossos

IS, Cobaleda C, Sanchez-Garcia I. A novel molecular mechanism involved

in multiple myeloma development revealed by targeting MafB to

hematopoietic progenitors. The EMBO Journal. 2012 Sep 12;31(18):3704-

3717. Epub 2012 Aug 17.

23. Vicente-Duenas C, Fontan L, Gonzalez-Herrero I, Romero-Camarero I,

Segura V, Aznar MA, Alonso-Escudero E, Campos-Sanchez E, Ruiz-Roca

L, Barajas-Diego M, Sagardoy A, Martinez-Ferrandis JI, Abollo-Jimenez F,

Bertolo C, Penuelas I, Garcia-Criado FJ, Garcia-Cenador MB, Tousseyn

T, Agirre X, Prosper F, Garcia-Bragado F, McPhail ED, Lossos IS, Du MQ,

Flores T, Hernandez-Rivas JM, Gonzalez M, Salar A, Bellosillo B, Conde

E, Siebert R, Sagaert X, Cobaleda C, Sanchez-Garcia I, Martinez-Climant

JA. Expression of MALT1 oncogene in hematopoietic stem/progenitor

cells recapitulates the pathogenesis of human lymphoma in mice. Proc

8

Natl Acad Sci USA. 2012 Jun 26;109(26):10534-10539. Epub 2012 Jun

11.

24. Warsch S, Hosein PJ, Morris MI, Teomete U, Benveniste R, Chapman JR,

Lossos IS. Progressive multifocal leukoencephalopathy following

treatment with bendamustine and rituximab International Journal of

Hematology. 2012 Aug; 96(2):274-278. Epub 2012 Jun 9.

25. Cubedo E, Gentles AJ, Huang C, Natkunam Y, Bhatt S, Lu X, Jiang X,

Romero-Camarero I, Freud A, Zhao S, Bacchi CE, Martínez-Climent JA,

Sánchez-García I, Melnick A, Lossos IS. Identification of LMO2

transcriptome and interactome in diffuse large B-cell lymphoma. Blood.

2012 Jun 7; 119(23):5478-5491. Epub 2012 Apr 19.

26. Braggio E, Dogan A, Keats JJ, Chng WJ, Huang G, Matthews JM, Maurer

MJ, Law ME, Bosler DS, Barrett M, Lossos IS, Witzig T, Fonseca R.

Genomic analysis of marginal zone and lymphoplasmacytic lymphomas

identified common and disease-specific abnormalities. Modern Pathology. 2012 May; 25(5):651-660. Epub 2012 Feb 3.

27. Zhu D, Lossos C, Chapman-Fredricks JR, Matthews JM, Ikpatt OF, Ruiz

P, Lossos IS. Biased Use of the IGHV4 Family and Evidence for Antigen

Selection in Chlamydophila psittaci-Negative Ocular Adnexal Extranodal

Marginal Zone Lymphomas. PloS ONE. 2011; 6(12):e29114. Epub 2011

Dec 27.

28. Warsch S, Hosein PJ, Maeda LS, Alizadeh AA, Lossos IS. A retrospective

study evaluating the efficacy and safety of bendamustine in the treatment

of mantle cell lymphoma. Leukemia Lymphoma. 2012 Jul; 53(7):1299-

1305. Epub 2012 Jan 31.

29. Dagan LN, Jiang X, Bhatt S, Cubedo E, Rajewsky K, Lossos IS. miR-155

Regulates HGAL Expression and Increases Lymphoma Cell Motility.

Blood. 2012 Jan 12; 119(2):513-520. Epub 2011 Nov 16.

30. Hosein PJ, Craig MD,Tallman MS, Boccia RV, Hamilton BL, Lewis JJ,

Lossos IS. A multicenter phase II study of darinaparsin in relapsed or

9

refractory Hodgkin’s and non-Hodgkin’s lymphoma. American Journal of

Hematology. 2012 Jan; 87 (1):111-114. Epub 2011 Nov 12.

31. Cerhan JR, Natkunam Y, Morton LM, Maurer MJ, Asmann Y, Habermann

TM, Vasef MA, Cozen W, Lynch CF, Allmer C, Slager SL, Lossos IS,

Chanock SJ, Rothman N, Hartge P, Dogan A, Wang SS. LIM domain only

2 protein expression, LMO2 germline genetic variation, and overall

survival in diffuse large B-cell lymphoma in the pre-rituximab era.

Leukemia Lymphoma. 2012 Jun; 53 (6):1105-1112. Epub 2012 Jan 3.

32. Dagklis A, Ponzoni M, Govi S, Cangi MG, Pasini E, Charlotte F, Vino A,

Doglioni C, Davi F, Lossos IS, Ntountas I, Papadaki T, Dolcetti R, Ferreri

AJ, Stamatopoulos K, Ghia P. Immunoglobulin gene repertoire in ocular

adnexal lymphomas: hints on the nature of the antigenic stimulation.

Leukemia. 2012 Apr; 26(4):814-821. Epub 2011 Oct 25.

33. Hosein PJ, Pastorini VH, Paes FM, Eber D, Chapman JR, Serafini AN,

Alizadeh AA, Lossos IS. Utility of positron emission tomography scans in

mantle cell lymphoma. Am J Hematol. 2011Oct; 86 (10):841-845. Epub

2011 Aug 22.

34. Morton LM, Cerhan JR, Hartge P, Vasef MA, NeppalliVT, Natkunam Y,

Dogan A, Dave BJ, Jain S, Levy R, Lossos IS, Cozen W, Davis S, Schenk

MJ, Maurer MJ,Lynch CF, Rothman N, Chatterjee N, Yu K, Staudt LM,

Weisenburger DD, Wang SS. Immunostaining to identify molecular

subtypes of diffuse large B-cell lymphoma in a population-based

epidemiologic study in the pre-rituximab era. Int J Mol Epidemiol Genet.

2011 Aug 30; 2 (3):245-52.

35. Beltran E, Fresquet V, Martinez-Useros J, Richter-Larrea JA, Sagardoy A,

Sesma I, Almada LL, Montes-Moreno S, Siebert R, Gesk S, Calasanz MJ,

Malumbres R, Rieger M, Prosper F, Lossos IS, Piris MA, Fernandez-

Zapico ME, Martinez-Climent JA. A cyclin-D1 interaction with BAX

underlies its oncogenic role and potential as a therapeutic target in mantle

cell lymphoma. Proc Natl Acad Sci USA. 2011 Jul 26; 108 (30):1261-1266.

10

36. Lossos C, Ferrell A, Duncan R, Lossos IS. Association Between Non

Hodgkin’s Lymphomas and Renal Cell Carcinoma. Leukemia Lymphoma.

2011 Dec; 52 (12): 2254-2261. Epub 2011 Aug 24.

37. Cubedo E, Maurin M, Jiang X, Lossos IS, Wright KL. PRDM1/Blimp1

downregulates expression of germinal center genes LMO2 and HGAL.

FEBS J. 2011 Sep; 278 (17): 3065-3075. Epub 2011 Aug 2.

38. Alizadeh AA, Gentles AJ, Alencar AJ, Liu CL, Kohrt HE, Houot R,

Goldstein MJ, Zhao S, Natkunam Y, Advani RH, Gascoyne RD, Briones J,

Tibshirani RJ, Myklebust JH, Plevritis SK, Lossos IS, Levy R. Prediction of

survival in diffuse large B-cell lymphoma based on the expression of 2

genes reflecting tumor and microenvironment. Blood. 2011 Aug 4; 118

(5):1350-1358. Epub 2011 Jun 13.

39. Azambuja D, Natkunam Y, Biasoli I, Lossos IS, Anderson MW, Morais JC,

Spector N. Lack of association of tumor-associated macrophages with

clinical outcome in patients with classical Hodgkin’s lymphoma. Ann

Oncol. 2012 Mar; 23(3):736-742. Epub 2011 May 20.

40. Alencar AJ, Malumbres R, Kozloski GA, Advani RH, Talreja N, Chinichian

S, Birones J Natkunam Y, Sehn L, Gascoyne RD, Tibshirani R, Lossos IS.

MicroRNAs are Independent Predictors of Outcome in Diffuse Large B-cell

Lymphoma Patients Treated with R-CHOP. Clinical Cancer Research.

2011 Jun 15; 17 (12):4125-4135. Epub 2011 Apr 27.

41. Younes SF, Beck AH, Ohgami RS, Lossos IS, Levy R, Warnke RA,

Natkunam Y. The Efficacy of HGAL and LMO2 in the Separation of

Lymphomas Derived from Small B Cells in Nodal and Extranodal Sites,

Including the Bone Marrow. Am J Clin Pathol. 2011 May; 135 (5): 697-

708.

42. Temmins C, Zhao S, Lossos IS, Natkunam Y. HGAL protein expression

persists in disorders of germinal center dissolution: potential role of HGAL

in the germinal center microenvironment. Applied Immunohistochemistry &

Molecular Morphology. 2011; May; 19 (3): 266-272.

11

43. Malumbres R, Fresquet V, Roman-Gomez J, Bobadilla M, Robles EF,

Altobelli GG, Calasanz MJ, Smeland EB, Aznar MA, Agirre X, Martin-

Palanco V, Prosper F Lossos IS, Martinez-Climent JA. LMO2 expression

reflects the different stages of blast maturation and genetic features in B-

cell acute lymphoblastic leucemia and predicts clinical outcome.

Haematologica. 2011 Jul; 96 (7): 980-986. Epub 2011 Apr 1.

44. Lu X, Kazmierczak K, Jiang X, Jones M, Watt J, Helfman DM, Moore JR,

Szczesna-Cordary D, Lossos IS. Germinal center-specific protein human

germinal center associated lymphoma directly interacts with both myosin

and actin and increases the binding of myosin to actin. FEBS J. 2011 Jun;

278 (11):1922-1931. Epub 2011 Apr 20.

45. Baecklund E, Backlin C, Mansouri M, Klareskog L, Askling J, Iliadou AN,

Enblad G, Lossos IS, Natkunam Y, Rosenquist R. LMO2 protein

expression predicts survival in rheumatoid arthritis patients with diffuse

large B-cell Leuk Lymphoma. 2011 Jun; 52 (6):1146-1149. Epub 2011 Feb

28.

46. Morgensztern D, Walker GR, Koniaris LG, Lossos IS. Lack of survival in

patients with peripheral T-cell lymphoma: a Surveillance, Epidemiology,

and End Results analysis. Leukemia Lymphoma. 2011; Feb; 52 (2): 194-

204.

47. Bayraktar S, Bayraktar UD, Stefanovic A. Lossos IS. Primary ocular

adnexal mucosa-associated lymphoid tissue lymphoma MALT: Single

institution experience in a large cohort of patients. Br J Haematol. 2011

Jan; 152 (1):72-80. Epub 2010 Nov 18.

48. Hansra D, Montague N, Stefanovic A, Akunyili I, Harzand A, Natkunam Y,

De la Ossa M, Byrne GE, Lossos IS. Oral and extraoral plasmablastic

lymphoma: Similarities and differences in clinicopathological

characteristics. Am J Clin Pathol 2010; 134 (5): 710-719.

49. Jiang X, Lu X, McNamara G, Liu X, Cubedo E, Sarosiek KA, Sánchez-

García I, Helfman DM, Lossos IS. HGAL, a germinal center specific

protein, decreases lymphoma cell motility by modulation of the RhoA

12

signaling pathway. Blood. 2010 Dec. 9; 116 (24):5217-5227. Epub 2010

Sep 15.

50. Chao MP, Alizadeh AA, Tant C, Myklebust JH, Varghese B, Gill S, Jan M,

Cha AC, Chan CK, Tan BT, Park CY, Zhao F, Kohrt HE, Malumbres, R,

Briones J, Gascoyne RD, Lossos IS, Levy R, Weissman IL, Majeti R. Anti-

CD47 antibody synergizes with rituximab to promote phagocytosis and

eradicate non-Hodgkin lymphoma. Cell. 2010 Sep 3; 142 (5): 699-713.

51. Younes SF, Beck AH, Lossos IS, Levy R, Warnke RA, Natkunam Y.

Immunoarchitectural Patterns in Follicular Lymphoma: Efficacy of HGAL

and LMO2 in the detection of the interfollicular and diffuse components.

Am J Surg Pathol. 2010; 34:1266-1276

52. Durnick DK, Law ME, Maurer MJ, Natkunam Y, Levy R, Lossos IS, Kurtin

PJ, McPhail ED. Expression of LM02 Is associated with t(14;18)/ IGH-

BCL2 fusion but not BCL6 translocations in Diffuse Large B-Cell

Lymphoma. Am J Clin Pathol. 2010; 134:278-281.

53. Stefanovic A, Davis J, Murray T, Markoe A, Lossos IS. Treatment of

isolated primary intraocular lymphoma with high-dose methotrexate-based

chemotherapy and binocular radiation therapy: a single-institution

experience. Br J Haematol. 2010 Oct; 151 (1): 103-106.

54. Sarosiek KA, Cavallin LE, Bhatt S, Toomey NL, Natkunam Y, Blasini W,

Gentles AJ, Ramos JC, Mesri EA, Lossos, IS. Efficacy of bortezomib in a

direct xenograft model of primary effusion lymphoma. PNAS. 2010; 107

(29) 13069-13074.

55. Yoon SO, Zhang X, Freedman AS, Zahrieh D, Lossos IS, Li L, Choi YS.

Down-regulation of CD9 expression and its correlation to tumor

progression in B lymphomas. Am J Pathol. 2010; 177:377-386.

56. Bayraktar S, Bayraktar UD, Ramos JC, Stefanovic A, Lossos IS. Primary

CNS lymphoma in HIV positive and negative patients: comparison of

clinical characteristics, outcome and prognostic factors. J Neurooncol.

2011 Jan; 101 (2):257-265.

13

57. Bayraktar S, Stefanovic A, Montague N, Davis J, Murray T, Lossos IS.

Central nervous system manifestations of marginal zone B-cell lymphoma.

Ann Hematol. 2010; 89 (10): 1003-1009.

58. Alizadeh AA, Bohen SP, Lossos C, Martinez-Climent JA, Ramos JC,

Cubedo-Gil E, Harrington WJ Jr, Lossos IS. Expression profiles of adult T-

cell leukemia-lymphoma and associations with clinical responses to

zidovudine and interferon alpha. Leuk Lymphoma. 2010 51 (7): 1200-16.

59. Sarosiek KA, Malumbres R, Nechushtan H, Gentles AJ, Avisar E, Lossos

IS. Novel IL-21 signaling pathway upregulates c-Myc and induces

apoptosis of diffuse large B-cell lymphomas. Blood. 2010; 115:570-580.

60. Anderson MW, Zhao S, Ai WZ, Tibshirani R, Levy R, Lossos IS,

Natkunam Y. C-C chemokin receptor 1 expression in human

hematolymphoid neoplasis. Am J Clin Pathol. 2010; 133:473-483.

61. Lossos IS, Hosein PJ, Morgensztern D, Coleman F, Escalon MP, Byrne

GE Jr, Rosenblatt JD, Walker GR. High rate and prolonged duration of

complete remissions induced by R-MACLO-IVAM-T- a modification of the

NCI 89-C-41 regimen, in patients with newly diagnosed mantle cell

lymphoma. Leuk Lymphoma. 2010; 51:406-414.

62. Byrne MM, Lossos IS, Koniaris LG. What is the institutional financial

impact of an MD-PhD Program without extramural funding? Teach Learn

Med. 2010; 22: 56 – 59.

63. Gratzinger D, Advani R, Zhao S, Talreja N, Tibshirani R, Shyam R,

Horning S, Sehn L, Farinha P, Briones J, Lossos IS, Gascoyne R,

Natkunam Y. Lymphoma cell VEGFR2 expression detected by

immunohistochemistry predicts poor overall survival in diffuse large B cell

lymphoma treated with immunochemotherapy (R-CHOP). Br J Haematol.

2010; 148: 235-244.

64. Alencar A, Pitcher D, Byrne GE Jr, Lossos IS. Primary Bone Lymphoma-

University of Miami experience. Leuk Lymphoma 2010;51:39-49.

65. Metcalf RA, Zhao S, Anderson MW, Lu ZS, Galperin I, Marinelli RJ,

Cherry AM, Lossos IS, Natkunam Y. Characterization of D-Cyclin proteins

14

in hematolymphoid neoplasms: lack of specificity of Cyclins D2 and D3

expression in lymphoma subtypes. Modern Pathology 2010; 23:420-433.

66. Azambuja D, Lossos IS, Biasoli I, Morais JC, Britto L, Scheliga A, Pulcheri

W, Natkunam Y, Spector N. Human Germinal center-Associated

Lymphoma (HGAL) protein expression is associated with improved failure-

free survival in Brazilian patients with Classical Hodgkin Lymphoma. Leuk

Lymphoma. 2009; 50:1830-1836.

67. Sarosiek KA, Nechushtan H, Lu X, Rosenblatt JD, Lossos IS. Interleukin-4

distinctively modifies responses of Germinal Center-like and Activated B-

cell-like diffuse large B-cell lymphomas to immuno-chemotherapy. Br J

Haematol. 2009; 147:308-318.

68. Salama ME, Lossos IS, Warnke RA, Natkunam Y. Immunoarchitectural

patterns in nodal marginal zone B-cell lymphoma: a study of 51 cases. Am

J Surg Pathol. 2009; 132:39-49.

69. Kalkanis D, Stefanovic A, Paes F, Escalon MP, Serafini A, Lossos IS.

FDG-PET/CT detection of asymptomatic late pulmonary toxicity in non-

Hodgkin lymphoma patients treated with rituximab-containing

chemotherapy. Leuk Lymphoma. 2009; 50:904-911.

70. Habermann TM, Lossos IS, Justice G, Vose JM, Wiernik PH, McBride K,

Wride K, Ervin-Haynes A, Takeshita K, Pietronigro D, Zeldis JB, Tuscano

JM. Lenalidomide oral monotherapy produces a high response rate in

patients with relapsed or refractory mantle cell lymphoma. Br J Haematol.

2009; 145:344-349.

71. Alencar AJ, Bustinza E, Barker J, Byrne GE Jr, Lossos IS. Hematodermic

tumor presenting with generalized skin involvement. J Clin Oncol. 2009;

27:3059-3061.

72. Malumbres R, Sarosiek KA, Cubedo E, Ruiz JW, Jiang X, Gascoyne RD,

Tibshirani R, Lossos IS. Differentiation-Stage-Specific Expression of

microRNAs in B-Lymphocytes and Diffuse Large B-Cell Lymphomas.

Blood. 2009; 113:3754-64.

15

73. Lu X, Malumbres R, Shields B, Natkunam Y, Jiang X, Tiganis T, Lossos

IS. PTP1B is a Negative Regulator of Interleukin 4-induced STAT6

Signaling. Blood. 2008; 112:4098-108.

74. Han HS, Escalon MP, Hsiao B, Serafini A, Lossos IS. High Incidence of

False Positive PET Scans in Patients with Aggressive Non-hodgkins

Lymphoma Treated with Rituximab-containing Regimens. Annals of

Oncology. 2009; 20(2):309-18.

75. Gratzinger D, Zhao S, West R, Rouse RV, Vogel H, Cubedo Gil E, Levy R,

Lossos IS, Natkunam Y. The transcriptional factor LMO2 is a robust

marker of vascular endothelium and vascular neoplasms and selected

other entities. Am J Clin Pathol. 2009 Feb; 131:264-278.

76. Malumbres R, Chen J, Tibshirani R, Johnson NA, Sehn LH, Natkunam Y,

Briones J, Advani R, Connors JM, Byrne GE, Levy R, Gascoyne RD,

Lossos IS. Paraffin-based 6-Gene Model Predicts Outcome in Diffuse

Large B-Cell Lymphoma Patients Treated with R-CHOP. Blood. 2008;

111:5509-5514.

77. Wiernik PH, Lossos IS, Tuscano JM, Justice G, Vose JM, Cole CE, Lam

W, McBride K, Wride K, Pietronigro D, Takeshita K, Ervin-Haynes A,

Zeldis JB, Habermann TM. Lenalidomide Monotherapy in Relapsed or

Refractory Aggressive Non-Hodgkin’s Lymphoma. J Clin Oncol. 2008;

26:4952-4957.

78. Stefanovic A, Morgensztern D, Fong T, Lossos IS. Pulmonary Marginal

Zone Lymphoma: A Single Center Experience and Review of the SEER

Database. Leuk Lymphoma. 2008; 49:1311-20.

79. Pfeifer I, Elsby R, Fernandez M, Faria PA, Nussenzveig DR, Lossos IS,

Fontoura BMA, Martin WD, Barber GN. NFAR-1 and -2 modulate

translation and are required for efficient host defense. PNAS. 2008;

105:4173-78.

80. Matthews JM, Moreno LI, Dennis J, Byrne GE Jr, Ruiz P, Dubovy SR,

Lossos IS. Ocular Adnexal Lymphoma: No Evidence for Bacterial DNA

16

Associated with Lymphoma Pathogenesis. Br J Haematol. 2008; 142:246-

249.

81. Baecklund E, Natkunam Y, Backlin C, Iliadou A, Askling J, Ekbom A,

Feltelius N, Klareskog L, Enblad G, Lossos IS, Levy R, Sundstrom C,

Rosenquist R. Expression of the human germinal-center-associated

lymphoma (HGAL) protein in diffuse large B-cell lymphomas in patients

with rheumatoid arthritis. Br J Haematol. 2008; 141:69-72.

82. Xie X, Sundram U, Natkunam Y, Kohler S, Hoppe RT, Kim YH, Cook JR,

Hammel J, Swerdlow SH, Guitart J, Smith MD, Bosler D, Listinsky C,

Lossos IS, Hsi ED. Expression of HGAL in primary cutaneous large B cell

lymphomas: Evidence for germinal center derivation of primary cutaneous

follicular lymphoma. Modern Pathology. 2008: 21:653-659.

83. Natkunam Y, Farinha P, Hsi ED, Hans CP, Tibshirani R, Sehn LH,

Connors JM, Gratzinger D, Rosado M, Zhao S, Pohlman B,

Wongchaowart N, Bast M, Avigdor A, , Schiby G, Nagler A, Byrne GE Jr,

Levy R, Gascoyne RD, Lossos IS. LMO2 protein expression predicts

survival in patients with diffuse large B-cell lymphoma treated with

anthracycline-based chemotherapy with and without rutiximab. J Clin

Oncol. 2008; 26: 447–454.

84. Gratzinger D, Zhao S, Tibshirani RJ, Hsi ED, Hans CP, Pohlman B, Bast

M, Avigdor A, Schiby G, Nagler A, Byrne GE Jr, Lossos IS, Natkunam Y.

Prognostic significance of VEGF, VEGF receptors, and microvessel

density in diffuse large B cell lymphoma treated with anthracycline-based

chemotherapy. Lab Invest. 2008; 88: 38-47.

85. Lu X, Chen J, Malumbres R, Cubedo Gil E, Helfman DM, Lossos IS.

HGAL, a lymphoma prognostic biomarker, interacts with the cytoskeleton

and mediates the effects of IL-6 on cell migration. Blood. 2007; 110: 4268-

77.

86. Malumbres R, Davis J, Ruiz P, Lossos IS. Somatically mutated

immunoglobulin IGVH @ genes without intraclonal heterogeneity indicate

17

a postgerminal centre origin of primary intraocular diffuse large B-cell

lymphomas. Br J Haematol. 2007, 138:749-55.

87. Calfa CJ, Lossos IS, Ruiz P, Davis JL. Ocular involvement as the initial

manifestation of a T-cell chronic lymphocytic leukemia. Am J Ophthalmol.

2007; 144:326-9.

88. Lu X, Chen J, Sasmono RT, Hsi ED, Sarosiek KA, Tiganis T, Lossos IS.

T-cell protein tyrosine phosphatase, distinctively expressed in activated-B-

cell-like diffuse large B-cell Lymphomas, is the nuclear phosphatase of

STAT6. Mol Cell Biol. 2007; 27:2166-79.

89. Natkunam Y, Vainer G, Chen J, Zhao S, Marinelli RJ, Hammer AS,

Hamilton-Dutoit S, Pikarsky E, Amir G, Levy R, Yisraeli JK, Lossos IS.

Expression of the RNA-binding protein VICKZ in normal hematopoietic

tissues and neoplasms. Haematologica. 2007; 92:176-83.

90. Chen J, Byrne GE Jr, Lossos IS. Optimization of RNA extraction from

formalin-fixed, paraffin-embedded lymphoid tissues. Diagn Mol Pathol.

2007; 16:61-72.

91. Ramos JC, Ruiz P Jr, Ratner L, Reis IM, Brites C, Pedroso C, Byrne GE

Jr, Toomey NL, Andela V, Harhaj EW, Lossos IS, Harrington WJ Jr. IRF-4

and c-Rel expression in antiviral-resistant adult T-cell leukemia/lymphoma.

Blood. 2007; 109: 3060–8.

92. Natkunam Y, Zhao S, Mason DY, Chen J, Taidi B, Jones M, Hammer AS,

Hamilton-Dutoit S, Lossos IS, Levy R. The Oncoprotein LMO2 is

expressed in normal germinal-center B cells and in human B-cell

lymphomas. Blood. 2007; 109:1636-42. 93. Natkunam Y, Hsi ED, Aoun P, Zhao S, Elson P, Pohlman B, Naushad H,

Bast M, Levy R, Lossos IS. Expression of the human germinal center-

associated lymphoma (HGAL) protein identifies a subset of classical

Hodgkin lymphoma of germinal center derivation and improved survival.

Blood. 2007; 109:298-305.

94. Rosado MF, Byrne GE Jr, Ding F, Fields KA, Ruiz P, Dubovy SR, Walker

GR, Markoe A, Lossos IS. Ocular adnexal lymphoma: a clinicopathologic

18

study of a large cohort of patients with no evidence for an association with

Chlamydia psittaci. Blood. 2006; 107:467-72.

95. Abdullah S, Morgensztern D, Rosado MF, Lossos IS. Primary

lymphoblastic B-cell lymphoma of the cranial dura mater: a case report

and review of the literature. Leuk Lymphoma. 2005; 46:1651-7.

96. Lu X, Nechushtan H, Ding F, Rosado MF, Singal R, Alizadeh AA, Lossos

IS. Distinct IL-4 induced gene expression, proliferation and intracellular

signaling in germinal center B-cell like and activated B-cell like diffuse

large cell lymphomas. Blood. 2005; 105: 2924-2932.

97. NatkunamY, Lossos IS, Taidi B, Zhao S, Lu X, Ding F, Hammer AS,

Marafioti T, Byrne Jr GE, Levy S, Warnke RA, Levy R. Expression of the

Human Germinal Center-Associated Lymphoma (HGAL) Protein, A New

Marker of Germinal Center B Cell Derivation. Blood. 2005; 105:3979-

3986.

98. Chen D, Padiernos E, Ding F, Lossos IS, Lopez CD. Apoptosis stimulating

protein p53-2(ASPP2/53BP2L) is an E2F target gene. Cell Death Differ.

2005; 12: 358-368.

99. Lossos IS, Czerwinski DK, Alizadeh AA, Wechser MA, Tibshirani R,

Botstein D, Levy R. Prediction of survival in diffuse large B-cell lymphoma

based on the expression of six genes. N Eng J Med, 2004; 350: 1828-

1837.

100. Lossos IS, Levy R, Alizadeh AA. AID is expressed in germinal center B-

cell like and activated B-cell like diffuse large-cell lymphoma and is not

correlated with intraclonal heterogeneity. Leukemia 2004; 18:1775-1779.

101. Morgensztern D, Rosado MF, Silva O, Santos ES, Abdullah SA, Goodman

M, Hamilton-Nelson K, Rosenblatt JD, Lossos IS. Prevalence of hepatitis

C infection in patients with non-Hodgkin's lymphoma in South Florida and

review of the literature. Leuk Lymphoma, 2004, 45:2459-2464.

102. Rosado MF, Morgensztern D, Peleg M, Lossos IS. Primary diffuse large

cell lymphoma of the mandible. Leuk Lymphoma, 2004; 45: 1049-1053.

19

103. Morgensztern D, Rosado MF, Serafini AN, Lossos IS. Somatostatin

receptor scintigraphy in MALT lymphoma of the lacrimal gland treated with

rituximab. Leuk Lymphoma, 2004; 45: 1275-1278.

104. Lossos IS, Akasaka T, Martinez-Climent JA, Siebert R, Levy R. The BCL6

gene in B-cell lymphomas with 3q27 translocations is expressed mainly

from the rearranged allele irrespective of the partner gene. Leukemia

2003; 17:1390-1397.

105. Lossos IS, Czerwinski DK, Wechser MA, Levy R. Optimization of

quantitative real-time RT-PCR parameters for the study of lymphoid

malignancies. Leukemia. 2003; 17:789-95.

106. Lossos IS, Alizadeh AA, Rajapaksa R, Tibshirani R, Levy R. HGAL is a

novel interleukin-4-inducible gene that strongly predicts survival in diffuse

large B-cell lymphoma. Blood. 2003; 101:433-440.

107. Martinez-Climent JA, Alizadeh AA, Segraves R, Blesa D, Rubio-Moscardo

F, Albertson DG, Garcia-Conde J, Dyer MJS, Levy R, Pinkel D, Lossos IS.

Transformation of follicular lymphoma to diffuse large cell lymphoma is

associated with a heterogeneous set of DNA copy number and gene

expression alterations. Blood. 2003; 101:3109-3117.

108. Akasaka T, Lossos IS, Levy R. BCL6 gene translocations in follicular

lymphoma: a harbinger of eventual transformation to diffuse aggressive

lymphoma. Blood. 2003; 102:1443-1448.

109. Do B, Lossos IS, Thorstenson Y, Oefner P, Levy R. Analysis of FAS

(CD95) gene mutations in higher-grade transformation of follicle center

lymphoma. Leuk Lymphoma. 2003; 44:1317-1323.

110. Lossos IS, Alizadeh AA, Diehn M, Warnke R, Thorstenson Y, Oefner PJ,

Brown PO, Botstein D, Levy R. Transformation of Follicular Lymphoma to

Diffuse Large Cell Lymphoma: alternative patterns with increased or

decreased expression of c-myc and its regulated genes. Proc Natl Acad

Sci U S A. 2002; 99: 8886-8891.

111. Lossos IS, Natkunam Y, Levy R, Lopez CD. Apoptosis Stimulating Protein

of p53 (ASPP2) Expression Differs in Diffuse Large B-Cell and Follicular

20

Center Lymphoma: Correlation With Clinical Outcome. Leuk Lymphoma.

2002; 43:2309-2317.

112. Lossos IS, Warnke R, Levy R. BCL-6 mRNA expression in higher-grade

transformation of follicle center lymphoma: correlation with somatic

mutations in the 5’ regulatory region of the BCL-6 gene. Leukemia. 2002;

16:1857-1862.

113. Lossos IS, Or R, Ginzburg V, Christensen TG, Meshriki Y, Breuer R.

Cyclosporin A up-modulates bleomycin – induced pulmonary injury in

BALB/C mice. Respiration. 2002; 69: 344-349.

114. Huang JZ, Sanger WG, Greiner TC, Staudt LM, Weisenburger DD,

Pickering DL, Lynch JC, Armitage JO, Warnke RA, Alizadeh AA, Lossos

IS, Levy R, Chan WC. The t(14;18) defines a unique subset of diffuse

large B-cell lymphoma with a germinal center B-cell gene expression

profile. Blood. 2002; 99: 2285-2290.

115. Bokstein F, Lossos A, Lossos IS, Siegal T. CNS relapse of systemic non-

Hodgkin's lymphoma: results of treatment based on high-dose

methotrexate chemotherapy. Leuk Lymphoma. 2002; 43:587-593.

116. Lossos IS, Thorstenson Y, Wayne TY, Oefner PJ, Levy R, Chu G.

Mutation of the ATM gene is not involved in the pathogenesis of either

follicle center lymphoma or its transformation to higher-grade lymphoma.

Leuk Lymphoma. 2002; 43:1079-1085.

117. Auffermann-Greitzinger S, Lossos IS, Vayntrub TA, Leong W, Grumet FG,

Blume KG, Stockerl-Goldstein KE, Levy R, Shizuru JA. Rapid

establishment of dendritic cell chimerism in allogeneic hematopoietic cell

transplant recipients. Blood. 2002; 99:1442-1448.

118. Cantwell MJ, Wierda WG, Lossos IS, Levy R, Kipps TJ. T cell activation

following infection of primary follicle center lymphoma B cells with

adenovirus encoding CD154. Leukemia. 2001; 15:1451-1457.

119. Lossos IS, Jones CD, Warnke R, Natkunam Y, Kaizer H, Zehnder JL,

Tibshirani R, Levy R. The expression of single gene, BCL-6, strongly

21

predicts survival in patients with diffuse large B-cell lymphoma. Blood.

2001; 98:945-951.

120. Lossos IS, Jones CD, Zehnder JL, Levy R. A polymorphism in the BCL-6

gene is associated with follicle center lymphoma. Leuk Lymphoma.

2001;42: 1343-1350.

121. Berkman N, Kremer S, Or R, Lossos IS, Christensen TG, Goldstein RH,

Breuer R. Human recombinant interferon-α2a and interferon-αA/D have

different effects on bleomycin-induced lung injury. Respiration.

2001;68:169-177.

122. Strahilevitz J, Lossos IS, Verstandig A, Sasson T, Kori Y, Gillis S.

Vascular access via peripherally inserted central venous catheters

(PICCs): Experience in 40 patients with acute myeloid leukemia at a single

institution. Leuk Lymphoma. 2001;40:365-371.

123. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A,

Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T,

Hudson J, Jr., Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC,

Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Staudt LM, et al.

Distinct types of diffuse large B-cell lymphoma identified by gene

expression profiling. Nature. 2000;403:503-511.

124. Lossos IS, Levy R. Mutation analysis of the 5' noncoding regulatory region

of the BCL-6 gene in non-Hodgkin lymphoma: evidence for recurrent

mutations and intraclonal heterogeneity. Blood. 2000;95:1400-1405.

125. Lossos IS, Breuer R, Intrator O, Lossos A. Cerebrospinal fluid lactate

dehydrogenase isoenzyme analysis for the diagnosis of central nervous

system involvement in hematooncologic patients. Cancer. 2000;88:1599-

1604.

126. Lossos IS, Okada CY, Tibshirani R, Warnke R, Vose JM, Greiner TC,

Levy R. Molecular analysis of immunoglobulin genes in diffuse large B-cell

lymphomas. Blood. 2000;95:1797-1803.

127. Lossos IS, Alizadeh AA, Eisen MB, Chan WC, Brown PO, Botstein D,

Staudt LM, Levy R. Ongoing immunoglobulin somatic mutation in germinal

22

center B cell-like but not in activated B cell-like diffuse large cell

lymphomas. Proc Natl Acad Sci U S A. 2000;97:10209-10213.

128. Lossos IS, Levy R. Higher-grade transformation of follicle center

lymphoma is associated with somatic mutation of the 5' noncoding

regulatory region of the BCL- 6 gene. Blood. 2000;96:635-639.

129. Lossos IS, Izbicki G, Or R, Goldstein R, Breuer R. The effect of suramine

on Bleomycine-induced lung injury. Life Sci. 2000;67:2873-2881.

130. Sosna J, Lossos IS, Libson E. Hodgkin's lymphoma of the urinary bladder.

Clin Radiol. 2000;55:405-406.

131. Lossos IS, Tibshirani R, Narasimhan B, Levy R. The inference of antigen

selection on Ig genes. J Immunol. 2000;165:5122-5126.

132. Raanani P, Shpilberg O, Gillis S, Avigdor A, Hardan I, Berkowicz M, Sofer

O, Lossos I, Chetrit A, Ben-Yehuda D, Ben-Bassat I. Salvage therapy of

refractory and relapsed acute leukemia with high dose mitoxantrone and

high dose cytarabine. Leuk Res. 1999;23:695-700.

133. Kremer S, Breuer R, Lossos IS, Berkman N, Christensen TG, Connor

MW, Goldstein RH, Or R. Effect of immunomodulators on bleomycin-

induced lung injury. Respiration. 1999;66:455-462.

134. Laxer U, Lossos IS, Gillis S, Or R, Christensen TG, Goldstein RH, Breuer

R. The effect of enoxaparin on bleomycin-induced lung injury in mice. Exp

Lung Res. 1999;25:531-541.

135. Lossos IS, Matzner Y. Anticardiolipin antibodies in myelodysplastic

syndromes. Acta Haematol. 1999;101:161-162.

136. Lossos IS, Paltiel O, Polliack A. Salvage chemotherapy using a

combination of fludarabine and cyclophosphamide for refractory or

relapsing indolent and aggressive non-Hodgkin's lymphomas. Leuk

Lymphoma. 1999;33:155-160.

137. Lossos IS, Intrator O, Berkman N, Breuer R. Lactate dehydrogenase

isoenzyme analysis for the diagnosis of pleural effusion in haemato-

oncological patients. Respir Med. 1999;93:338-341.

23

138. Alizadeh A, Eisen M, Davis R, Ma C, Sabet H, Tran T, Powell J, Yang L,

Marti G, Moore D, Hudson J, Chan W, Greiner T, Weisenburger D,

Armitage J, Lossos IS, Levy R, Botstein D, Brown P, Staudt L. The

lymphochip: A specialized cDNA microarray for the genomic-scale

analysis of gene expression in normal and malignant lymphocytes. Cold

Spring Harbor Proc. Symp. Quant. Biol. 1999;64:71-7818.

139. Yossepowitch O, Lossos A, Lossos IS. Sudden hearing loss following

acute hepatitis. Postgrad Med J. 1999;75:309-312.

140. Bogomolski-Yahalom V, Lossos IS, Okun E, Sherman Y, Lossos A,

Polliack A. Intravascular lymphomatosis--an indolent or aggressive entity?

Leuk Lymphoma. 1998;29:585-593.

141. Glazer M, Breuer R, Berkman N, Lossos IS, Kapelushnik J, Nagler A,

Naparstek E, Kramer MR, Lafair J, Engelhard D, Or R. Use of fiberoptic

bronchoscopy in bone marrow transplant recipients. Acta Haematol.

1998;99:22-26.

142. Lossos IS, Bogomolski-Yahalom V, Matzner Y. Anticardiolipin antibodies

in acute myeloid leukemia: prevalence and clinical significance. Am J

Hematol. 1998;57:139-143.

143. Lossos IS, Yossepowitch O, Kandel L, Yardeni D, Arber N. Septic arthritis

of the glenohumeral joint. A report of 11 cases and review of the literature.

Medicine (Baltimore). 1998;77:177-187.

144. Lossos IS, Breuer R, Shriki M, Or R. Peribronchial lymphocyte activation

in bleomycin-induced lung injury. Life Sci. 1998;63:1183-119316.

145. Lossos IS, Bogomolski-Yahalome V, Yehuda O, Ben-Neriah S, Ben-

Yehuda D, Leizerowitz R, Polliack A. A novel translocation (1;2)(p34;p21-

22) in acute myelomonoblastic leukemia. Cancer Genet Cytogenet.

1998;106:78-79.

146. Sklair-Levy M, Libson Y, Lossos IS, Bugomolsky-Yahalom V. Splenic

calcifications caused by Trichosporon beigelli infection: CT and ultrasound

demonstration. Eur Radiol. 1998;8:922-924.

24

147. Ben Yehuda A, Lossos IS, Or R, Ben Chetrit E, Goldstein RH, Conner

MW, Breuer R. Colchicine does not ameliorate bleomycin-induced

pulmonary injury in hamsters. Pulm Pharmacol Ther. 1997;10:61-65.

148. Da'as N, Lossos IS, Yahalom V, Rund D, Wolf DG, Zelig O, Ben-Yehuda

D. Candida abscess of the thyroid in a patient with acute lymphocytic

leukemia. Eur J Med Res. 1997;2:365-366.

149. Golan G, Lebensart PD, Lossos IS. Ultrasound diagnosis and follow-up of

testicular monocytic leukemia. J Clin Ultrasound. 1997;25:453-455.

150. Lossos IS, Okon E, Bogomolski-Yahalom V, Ron N, Polliack A. Sinus

histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease):

report of a patient with isolated renotesticular involvement after cure of

non-Hodgkin's lymphoma. Ann Hematol. 1997;74:41-44.

151. Yossepowitch O, Amir G, Safadi R, Lossos IS. Ischemic hepatitis

associated with toxic epidermal necrolysis in a cirrhotic patient treated with

cefuroxime. Eur J Med Res. 1997;2:182-184.

152. Lossos IS, Breuer R, Intrator O, Sonenblick M. Differential diagnosis of

pleural effusion by lactate dehydrogenase isoenzyme analysis. Chest.

1997;111:648-65114.

153. Lossos IS, Or R, Goldstein RH, Conner MW, Breuer R. Amelioration of

bleomycin-induced pulmonary injury by cyclosporin A. Exp Lung Res.

1996;22:337-349.

154. Lossos IS, Berger S, Gomori M, Leibovich G, Matzner Y. Hearing loss and

leukocytosis. Postgrad Med J. 1996;72:183-185

155. Lossos IS, Yossepowitch O, Amir G, Oren R. Naproxen associated

leukocytoclastic vasculitis. Harefuah. 1996;130:600-602.

156. Or R, Lossos IS, Hirschfeld E, Breuer R. Effect of interleukin-2 and

interleukin-4 on lymphocytes from peribronchial lymphatic tissue. Exp

Lung Res. 1996;22:245-253.

157. Breuer R, Lossos IS, Or R, Krymsky M, Dagan A, Yedgar S. Abatement of

bleomycin-induced pulmonary injury by cell-impermeable inhibitor of

phospholipase A2. Life Sci. 1995;57:L237-240.

25

158. Lossos IS, Breuer R, Or R, Strauss N, Elishoov H, Naparstek E, Aker M,

Nagler A, Moses AE, Shapiro M, et al. Bacterial pneumonia in recipients of

bone marrow transplantation. A five-year prospective study.

Transplantation. 1995;60:672-678.

159. Yedgar S, Dan P, Dagan A, Ginsburg I, Lossos IS, Breuer R. Control of

inflammatory processes by cell-impermeable inhibitors of phospholipase

A2. Agents Actions Suppl. 1995;46:77-84.

160. Kaminski N, Lossos IS, Ben-Sira L, Laxer U, Jaffe R. Flank pain as a

presentation of pulmonary embolism. Respir Med. 1995;89:65-66.

161. Lossos IS, Matzner Y. Hydroxyurea-induced fever: case report and review

of the literature. Ann Pharmacother. 1995;29:132-133.

162. Schwaber M, Lossos IS, Goldberg Y, Jaffe R, Kaminski N. Right-sided

endocarditis due to Staphylococcus aureus in a pregnant non-drug abuser

with normal heart valves. Infect Dis Clin Pract. 1995;4:453-455.

163. Arber N, Pras E, Copperman Y, Schapiro JM, Meiner V, Lossos IS,

Militianu A, Hassin D, Shai A, et al. Pacemaker endocarditis. Report of 44

cases and review of the literature. Medicine (Baltimore). 1994;73:299-305.

164. Lossos IS, Schwaber MJ, Levin T, Ackerman Z. Spontaneous peritonitis

caused by Streptococcus bovis. J Clin Gastroenterol. 1994;19:346.

165. Abolnik IZ, Lossos IS, Gillis D, Breuer R. Primary spontaneous

pneumothorax in men. Am J Med Sci. 1993;305:297-303.

166. Mevorach D, Lossos IS, Oren R. Cefuroxime-induced fever. Ann

Pharmacother. 1993;27:881-882.

167. Oren R, Lossos IS. Elevated creatine phosphokinase and creatine

phosphokinase-MB in hyperventilation. Am J Med. 1993;94:113.

168. Leibowitz G, Amir G, Lossos IS, Eliakim R. Autoimmune polyglandular

failure associated with malabsorption and gastric carcinoid tumour. J

Intern Med. 1993;234:625-629.

169. Lossos IS, Oren R. Recurrent infective endocarditis. Postgrad Med J.

1993;69:816-818.

26

170. Lossos IS, Felsenstein I, Breuer R, Engelhard D. Food-borne outbreak of

group A beta-hemolytic streptococcal pharyngitis. Arch Intern Med.

1992;152:853-855.

171. Abolnik IZ, Lossos IS, Zlotogora J, Brauer R. On the inheritance of primary

spontaneous pneumothorax. Am J Med Genet. 1991;40:155-158.

172. Abolnik I, Lossos IS, Breuer R. Spontaneous pneumomediastinum. A

report of 25 cases. Chest. 1991;100:93-95.

173. Putterman C, Lossos IS. Author, verify your references! Or, the accuracy

of references in Israeli medical journals. Isr J Med Sci. 1991;27:109-112.

174. Breuer R, Lossos IS, Lafair JS, Engelhard D. Utility of bronchoalveolar

lavage in the assessment of diffuse pulmonary infiltrates in non-AIDS

immunocompromised patients. Respir Med. 1990;84:313-316.

175. Gotterer N, Lossos I, Breuer R. Pancoast's syndrome caused by primary

pulmonary hydatid cyst. Respir Med. 1990;84:169-170.

176. Lossos IS, Breuer R. Endobronchial metastasis from parotid gland tumour.

J R Soc Med. 1990;83:191.

177. Lossos IS, Abolnik I, Breuer R. Pneumomediastinum: a complication of

exposure to bromine. Br J Ind Med. 1990;47:784.

178. Lossos I, Israeli A, Zajicek G, Berry EM. Diagnosis deferred--the clinical

spectrum of diagnostic uncertainty. J Clin Epidemiol. 1989;42:649-657.

179. Lossos IS, Breuer R. Round pneumonia. Isr J Med Sci. 1989;25:713-714.

180. Lossos IS, Breuer R, Lafair JS. Endotracheal neurofibroma in a patient

with von Recklinghausen's disease. Eur Respir J. 1988;1:464-465.

Review Articles

1. Hoffman J, Lossos IS. Commentary for Leukemia and Lymphoma:

Lymphoma Associated Hemophagocytic Syndrome – It’s Going Viral.

Leukemia and Lymphoma. 2014 Sep;55(9):1964-5. Epub 2014 Jun 16.

2. Lossos IS. The DNA methylome – a novel biomarker. Blood. 2014 Mar

13;123(11):1627-8.

27

3. Deutsch YE, Lossos IS, Rosenblatt JD. Brentuximab vedotin for Hodgkin

lymphoma and systemic anaplastic large cell lymphoma: a review of

clinical experience and future directions. International Journal of

Hematology Oncology, 2013 2 (6), 1-11.

4. Ramos JC, Lossos IS. Newly Emerging Therapies Targeting Viral-related

Lymphomas. Current Oncology Reports. 2011 Oct; 13 (5): 416-426.

5. Lossos IS, Gascoyne RD. Transformation of follicular lymphoma, Best

Practice & Research Clinical Haematology. 2011 June; 24 (2): 147-163.

Epub 2011 May 6.

6. Lossos IS. BLIMP1 against Lymphoma: The Verdict is Reached. Cancer

Cell. 2010; Dec 14; 18 (6): 537-9.

7. Malumbres R, Lossos IS. Expression of miRNAs in Lymphocytes: A

Review. Methods Mol Biol. 2010; 667:129-143.

8. Stefanovic A, Lossos IS. Primary testicular lymphoma: the site matters.

Leuk Lymphoma. 2010; 51 (7): 1159-60.

9. Hosein PJ, Lossos IS. The evolving role of 18-F-FDG PET in patients with

aggressive non-Hodgkin’s Lymphoma. European Journal of Clinical &

Medical Oncology. 2010.Vol 2, Issue 1:131-138.

10. Stefanovic A, Lossos IS. Rare PTCLs: treatment lagging behind

pathobiologic advances. Oncology. 2010; 24:101-102.

11. Mann KK, Wallner B, Lossos IS, Miller WH Jr. Darinaparsin: a novel

organic arsenical with promising anti-cancer Activity. Expert Opin Investig

Drugs. 2009;18:1727-1734.

12. Stefanovic A, Lossos IS. Extranodal marginal zone lymphoma of the

ocular adnexa. Blood. 2009; 114:501-510.

13. Escalon MP, Lossos IS. Pharmacotherapy of large B-cell lymphoma.

Expert Opin Pharmacother. 2008; 9:2247-2258.

14. Lossos IS. Diffuse Large B Cell Lymphoma: From Gene Expression

Profiling to Prediction of Outcome. Biology of Blood and Marrow

Transplantation. 2008; 14:108-111.

28

15. Alizadeh AA, Lossos IS. Double trouble in follicular lymphoma: a rare and

unusual synergy of oncogenes in the germinal center. Leukemia and

Lymphoma. 2008; 49:3, 377-380.

16. Lossos IS. The endless complexity of lymphocyte differentiation and

lymphomagenesis: IRF-4 downregulates BCL6 expression. Cancer Cell.

2007 12: 189-191.

17. Lossos IS. IL-4 in lymphoma- does the target matter? Leuk Lymphoma.

2007; 48:1261-1263.

18. Morgensztern D, Martin MG, Lossos IS. Gene expression profiling in

diffuse large B-cell lymphoma. Leuk Lymphoma. 2007,48:669-682.

19. Lossos IS. Closing the loop: p53-BCL6 feedback. Blood. 2006; 107:1248-

1249.

20. Lossos IS, Morgensztern D. Prognostic biomarkers in diffuse large B-cell

lymphoma. J Clin Oncol. 2006, 24:995-1007.

21. Lossos IS. Molecular pathogenesis of diffuse large B-cell lymphoma. J

Clin Oncol. 2005; 23:6351-6357.

22. Morgensztern D, Lossos IS. Molecular prognostic factors in diffuse large

B-cell lymphoma. Curr Treat Options Oncol. 2005; 6:269-277.

23. Lossos IS. Higher-grade transformation of follicular lymphoma – a

continuous enigma. Leukemia. 2005; 19:1331-1333.

24. Lossos IS, Morgensztern D. Non-Hodgkin’s lymphoma in the microarray

era. Clin Lymphoma. 2004; 5:128-129.

25. Lossos IS, Levy R. Higher-grade transformation of follicle center

lymphoma: phenotypic tumor progression associated with diverse genetic

lesions. Sem Cancer Biology. 2003; 13:191-202.

26. Lossos IS, Levy R. Diffuse large B-cell lymphoma – insights gained from

gene expression profiling. Int J Hematology. 2003; 77:321-329.

27. Snider JV, Wechser MA, Lossos IS. Human disease characterization: real-

time quantitative PCR analysis of gene expression. Drug Discovery

Today. 2001;6: 1062-1067.

29

28. Kaminski N, Lossos IS, Breuer R. Nitric oxide in the respiratory system.

Harefuah. 1995; 128:173-175.

29. Breuer R, Lossos IS, Berkman N, Or R. Pulmonary complications of bone

marrow transplantation. Respir Med. 1993; 87 571-579.

30. Lossos IS, Breuer R. Endobronchial metastases (editorial). Harefuah.

1989; 116:339-340.

31. Lossos I, Breuer R. Pulmonary manifestations of rheumatoid arthritis.

Harefuah. 1989; 117:205-209.

32. Lossos I, Naparstek Y. Should asymptomatic ventricular premature beats

be treated? Harefuah. 1987; 113:180-182.

Letters to the Editor 1. Qing X, Sun N, French SW, Yue C, Montague N, Lossos IS. Oral and

extraoral plasmablastic lymphoma: similarities and differences in

clinicopathologic characteristics. Am J Clin Pathol. 2011 Jun; 135 (6):977-

978.

2. Stefanovic A, Lossos IS. Variability in the prevalence of Chlamydophila

psittaci infection in patients with OAML. Blood. 2009; 114: 3499-3500.

3. Alizadeh AA, Gentles AJ, Lossos IS, Levy R. Molecular outcome

prediction in diffuse large B-cell lymphoma. N Eng J Med. 2009; 360:2794-

2795.

4. Feilmeier MR, Lossos IS, Malumbres Rl, Schefler AC, Murray TG.

Successful use of semi-nested PCR for the diagnosis of primary

intraocular lymphoma [letter]. Leuk Lymphoma. 2008; 49:1612-1615.

5. Lossos IS, Morgensztern D, Blaya M, Alencar A, Pereira D, Rosenblatt J.

Rituximab for treatment of chemo-immunotherapy naive marginal zone

lymphoma [letter]. Leuk Lymphoma. 2007; 48:1630-1632.

30

6. Rosado MF, Morgensztern D, Sakher A, Ruiz P, Lossos IS. Chronic

lymphocytic leukemia-associated nephritic syndrome caused by focal

segmental glomerulosclerosis [letter]. Am J Hematol. 2004; 77:205-206.

7. Lossos IS, Akasaka T, Levy R. Response: Multiple BCL6 translocations

partners in individual cases of gastric lymphoma [letter]. Blood. 2003;

102:1932.

8. Lossos IS, Jacobs Y, Cleary ML, Levy R. Correspondence re: Akasaka, H.,

et al., Molecular anatomy of BCL6 translocation revealed by long-distance

polymerase chain reaction-based assay. Cancer Res., 60: 2335-2341,

2000 [letter]. Cancer Res. 2001; 61:7363-7364.

9. Lossos IS, Ben-Yehuda D. Cutaneous and subcutaneous necrosis

following dexrazoxane-CHOP therapy [letter]. Ann Pharmacother. 1999;

33:253-254.

10. Lossos IS. Comment: drug-induced hiccups [letter; comment]. Ann

Pharmacother. 1997; 31:1264-12659.

11. Halkin A, Lossos IS, Mevorach D. HMG-CoA reductase inhibitor-induced

impotence [letter]. Ann Pharmacother. 1996; 30:192.

12. Golan G, Lossos IS. Septicemia due to contaminated intravenous fluids: a

point to remember [letter]. Mil Med. 1995; 160:A12-13.

13. Golan G, Reichman JM, Lossos IS. Rectal examination: a potential hazard

to physicians [letter]. J Clin Gastroenterol. 1995; 21:173.

14. Lossos IS, Lossos A. Hazards of rapid administration of ceftriaxone

[letter]. Ann Pharmacother. 1994; 28:807-808.

15. Lossos IS, Matzner Y. Aplastic anemia associated with amiodarone

therapy [letter]. Acta Haematol. 1992; 87:213.

16. Lossos IS, Putterman C, Mainer Z. Massive haemothorax from central

venous catheterization: a note of caution [letter] [published erratum

appears in Arch Emerg Med 1993;Dec;10(4):390]. Arch Emerg Med. 1992;

9:335-338.

17. Lossos IS, Mevorach D, Oren R. Thiethylperazine treatment of

gastroparesis diabeticorum [letter]. Ann Pharmacother. 1992; 26:1016.

31

18. Lossos IS, Breuer R. Endobronchial metastasis from Hurthle cell thyroid

carcinoma [letter]. Chest. 1990; 97:768.

19. Lossos IS. Sources of endobronchial metastases [letter; comment]. Chest.

1990;98:1308-1309.

20. Lossos IS, Breuer R. A rare case of hiccups [letter]. N Engl J Med. 1988;

318:711-712.

Selected Refereed Abstracts 1. Reddy SA, Lossos I, Yuen A. Testicular lymphoma: The Stanford

experience. Blood 2001; 98: 552.

2. Lossos IS, Jones CD, Zehnder JL, Warnke R, Levy R. Real-time PCR

assay for quantitation of BCL-6 mRNA. Blood 2001; 96: 4423.

3. Sosna J, Chissin R, Klein M, Lossos IS, Polliack A, Libson E. The

incidence and clinical relevance of discordant results between 67Gallium

SPECT scintigraphy and computerized tomography in lymphoma:

Experience with 175 patients. Radiology 2000; 217:869.

4. Gillis S, Lossos IS, Libster D, Paltiel O, Polliack A. Stanford V regimen in

advanced-stage (III-IV) Hodgkin's disease. Blood 1998; 92: 4012.

5. Polliack A, Paltiel O, Lossos IS. Late relapse 5 to 12 years after “cure” in

Hodgkin’s disease: primary relapse or second neoplasia? Leukemia

Lymphoma 1998; 29(suppl 1):158.

6. Sosna J, Klein M, Lossos IS, Libson E, Polliack A, Chisin R. Discordance

between 67-Gallium spect scintigraphy and computerized tomography in

the follow-up of HD patients. Leukemia Lymphoma.1998; 29(suppl 1):143

7. Sosna J, Klein M, Lossos IS, Paltiel O, Polliack A, Libson E. Discordance

between 67-Gallium SPECT scintigraphy and computerized tomography in

follow-up of lymphoma patients. Brit J Radiology.1998; 71(suppl):16.

8. Lossos A, Lossos IS, Cohen O, Or R, Siegal T. Acute inflammatory

demyelinating polyneuropathy ( AIDP ) associated with immunomodulating

agents and anti-cancer chemotherapy. J Neuro-Oncology. 1996; 30:123.

32

V. PROFESSIONAL

Funded Research Ongoing Co-PI: Izidore Lossos. Nanofabrication of Artificial Membranes to Investigate

Antigen Internalization in B cells. University of Miami, Dr. John T. Macdonald

Foundation, Biomedical Nanotechnology Institute (BioNIUM), 8/15/14 – 8/15/15,

$30,000.

PI: Izidore Lossos. The Role of LMO2 in Double Strand DNA repair and

Lymphoma Pathogenesis. University of Miami, Sylvester Developmental

Research Grant, 8/1/14 – 8/1/16, $100,000.

PI: Izidore Lossos. Significance and Function of HGAL in Lymphoma.

2R01CA109335-04-A1 NIH-NCI, 4/1/05 – 5/31/14, $173,595/year.

PI: Izidore Lossos. New Immunotherapeutic Approaches to Mantle Cell

Lymphoma. PROPOSAL M1101633 Lymphoma Research Foundation, 11/1/11 –

10/31/13, $100,000/year.

PI: Izidore Lossos. Pathophysicological Role and Targeting of MAPKs in DLBCL.

M1201432 Lymphoma Research Foundation, 8/1/12 – 7/31/14, $125,000/year.

Mentor: Izidore Lossos. Regulation of NF-kB Signaling Pathway in DLBCL by

MicroRNAs. M1200495 Lymphoma Research Foundation, 1/1/12 – 12/31/13,

$105,000.

Funded Research Completed Co-PI: Izidore Lossos: Targeting Cell Cycle and Apoptosis Pathways to Eradicate

Mantle Cell Lymphoma. PROPOSAL M1001993, 10/1/10 – 9/30/12, $25,000.

PI: Izidore Lossos. Prognostic Models in Diffuse Large B-Cell Lymphoma.

33

5-R01-CA-122105-04 NIH-NCI, 9/24/07 – 7/31/12, $243,974/year.

PI: Izidore Lossos: A Single Arm, Safety and Efficacy Study of Ofatumumab in

Combination with ICE or DHAP Chemotherapy in Relapsed or Refractory

Aggressive Lymphoma Prior to Autologous Stem Cell Transplantation.

OMB110927 Glaxo/Smithkline, 9/19/08 – 9/18/12, $41,230.

PI: Izidore Lossos: A Phase II Trial of MLN8237, an Oral Aurora A Kinase

Inhibitor, in Adult Patients with Aggressive Non-Hodgkin’s Lymphoma. C14004

Millennium, 6/16/09 – 6/15/13, $46,219.

Co-PI: Izidore Lossos. A Phase II Trial of Combination Bortezomib and Rituximab

as Front-Line Therapy for Low-Grade Hodgkin’s Lymphoma. 215058 Millennium,

3/23/07 – 1/18/12, $12,946.

PI: Izidore Lossos. A Phase II, Multicenter, Single-Arm, Open Label Study to

Evaluate the Safety and Efficacy of Signal-Agent Lenalidomide (Revlimid) in

Subjects with Relapsed or Refractory Aggressive Non-Hodgkin’s Lymphoma.

CC5013NHL003 Celgene, 1/18/07 – 1/26/12, $69,681.

PI: Izidore Lossos: miRNAs in B Cell Differentiation and Cancer. Fidelity

Foundation 4/1/09 – 3/31/12, $204,154/year.

PI: Izidore Lossos: A Phase 1 Dose Escalation Study of Darinaparsin in

Combination with Chop. SGL1003 Clinical Trial, 1/1/11 – 1/10/15.

PI: Izidore Lossos: Significance and Function of H-GAL in Lymphoma.

3-R01-CA-109335-94-A1S1 NIH-NCI, 7/1/10 – 6/30/11.

PI: Izidore Lossos: Phase II Study of ZIO-101 in Advanced Blood and Bone

Marrow Cancers. SGL2003 Ziopharm, 7/12/07 – 7/11/11, $43,977.

34

Co-PI: Izidore Lossos: VICKZ Protein in Germinal Centers and Germinal Center

B-cell Lymphomas: Biology, Prognosis and Treatment. 2005205 United States-

Israel Binational Science Foundation, 9/1/06 – 8/31/10 $5,000.

PI: Izidore Lossos: AIDS-Related Lymphomas – Prognostic Markers (Project 2).

07BR-01 Bankhead-Coley, 7/1/07 – 6/30/09, $206,351.

PI: Izidore Lossos: Tissue & Molecular (Core B). 07BR-01 Bankhead-Coley,

7/1/07 – 6/30/09, $89,128.

PI: Izidore Lossos: Computational Modeling of Cancer Biology

U56 CA112973 NIH-NCI, 9/1/07 – 8/31/08, $45,328.

PI: Izidore Lossos: Prognostic Models in Diffuse Large B-Cell Lymphoma.

06BCBG113 BC FL Biomed, 1/1/07 – 9/30/07, $190,476.

Co-PI: Izidore Lossos. A Phase I/II Study to Evaluate the Feasibility and

Tolerability of Treatment of Previously Untreated B Cell Chronic Lymphocitic

Leukemia (B-Cell) Patients with Recombinant Idiotype Conjugated to KLH (ID-

KLH) Administered with GM-CSF. 200511 Genitope, 6/1/06 - 5/31/10, $ 32,074.

Mentor: Izidore Lossos. Gene Model for DLBCL Prognosis from Paraffin

Samples. 72679114B Caja Madrid, 7/1/06 – 6/30/08, $23,189.

Co-PI: Izidore Lossos : Phase II Trial of Motexafin Gadolinium (MGD) in Patients

with Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma. PCYC0221

Pharmacyclics, 6/1/2004 - 6/30/2007, $43,205.

Co-PI: Izidore Lossos: A Multicenter, Single-Arm, Open-Label Study to Evaluate

the Safety and Efficacy of Single-Agent Lenalidomide (REVLIMID, CC-5013) in

35

Subjects with Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma.

CC5013NHL002 Celgene, 8/3/2005 – 7/30/2007, $36,150.

PI: Izidore Lossos. Title: Regulation of the expression of HGAL- a new IL-4

inducible gene that strongly predicts survival in diffuse large B-cell lymphoma.

2/1/03 – 1/31/04, SCCC, $35,000.

PI: Izidore Lossos. Title: Distinct IL-4 Effects and Signaling in Germinal Center-

Like and Activated B-Cell like Diffuse Large B-Cell Lymphoma. 2/1/04 –

1/31/2005. SCCC, $30,000.

PI: Izidore Lossos. Title: The possibility of ameliorating bleomycin-induced lung

injury by suramin. 11/97-10/98. Israel Ministry of Health, Chief Scientist's Office.

NIS $35,000.

Honors and Awards 2007 – Celgene Young Investigator Award for Achievements in Clinical

Hematology

2004, 2005, 2008, 2009, 2010, 2011 and 2012 America’s Top Doctors (5th 6th 7th

8th, 9th and 10th editions) Castle Connolly Medical LTD; ISBN 1-883769-90-6.

2005, 2006, 2007, 2008, 2009, 2010, 2011 and 2012 America’s Top Doctors for

Cancer (1st 2nd 3rd 4th 5th 6th and 7th editions) A Castle Connolly Guide

2011 – Recognized as Top Doctor by US News and World Report

2012 – Sylvester Comprehensive Cancer Center Outstanding Cancer Research

Award

Patents 7332280 Classification of patients having diffuse large B-cell lymphoma based on

expression of 6 genes

36

61/265567 Classification and outcome prediction of patients having diffuse large

B-cell lymphoma based on expression miRNAs.

13/253,491 Methods of Prognosis for Non-Hodgkin Lymphoma

Provisional:

UML-112 “aCD20-IL21 fusokine for treatment of lymphoma and other diseases.

Professional and Honorary Organizations Israel Medicine Association 1987-present

American Society of Hematology 2002-present

American Society of Clinical Investigators 2007-present.

American Society of Clinical Oncology 2009-present

Lymphoma Foundation - Advisory Board Member, 2009-present

Conference Oral Presentations or Invited Talks

2014, Society of Utah Medical Oncologists, Park City, Utah: ONCOLOGY

EXCHANGE: Evolving Treatment Strategies for Mantle Cell Lymphoma in Elderly

Patients

2014, International Congress on Molecular Targeting Therapy, Kibbutz

Hagoshrim, Israel: Novel Targeted Therapies in Lymphoma.

2014, 1st Annual Translational Studies in Multiple Myeloma and CLL Meeting,

Whistler, Canada: MAPK Pathways Signaling in B-cell Malignancies.

2013, 17th Annual CFAR Meeting Satellite Symposium, Miami CFAR AIDS

Malignancies Scientific Working Group and Sylvester Comprehensive Cancer

Center, Miami, FL: CD30 Targeting with Brentuximab Vedotin: A novel

Therapeutic Approach to Primary Effusion Lymphoma.

37

2013, Lymphoma and Myeloma: An international congress on Hematologic

Malignancies, Waldorf Astoria, New York, NY – HGAL and LMO2 in B-cell

Malignancies.

2013, University of Miami Miller School of Medicine, Miami, FL: Medical Grand

Rounds, HGAL – A simple gene with a complex function.

2012, John Theurer Cancer Center at Hackensack University Medical Center,

Hackensack, New Jersey – Grand Rounds: New Genes – New Insights: The

HGAL Story.

2012, 9th Annual Mantle Cell Lymphoma Scientific Workshop, Atlanta, Georgia:

A cyclin-D1 interaction with BAX underlies its oncogenic role and potential as a

therapeutic target in mantle cell lymphoma.

2011, International Symposium: New frontiers In Hematological Malignancies,

Pamplona, Spain, November 16-18th. Prognostic biomarkers in B-cell lymphomas

2011, Spanish Hematology Meeting, Zaragoza, Spain: LIII Renuion Nacional

Sehh-XXVII Nacional Seth. DLBCL-Novel insights

2011, NCI Translational Science Meeting, Washington DC: Prognostic

Biomarkers in Lymphoma

2011, Ohio State University Comprehensive Cancer Center (OSUCCC) – James

Grand Rounds: DLBCL – New Insights

2010, ZymoGenetics Portfolio Management Group (PMG) Committee Meeting,

Seattle: Diffuse Large B-cell Lymphoma and IL-21

2010, Volfson Hospital, Israel: DLBCL – Current and Novel Therapies

2010, North Shore Medical Center, Medical Education Speakers Network, Miami:

Current and Novel Therapies of Diffuse Large B-cell Lymphoma

2010, Roswell Park Cancer Institute Medical Grand Rounds, New York:

Biomarkers in DLBCL: from Prognostic Significance to Molecular Function

2010, East Orange NJ VA Medical Center NHL VA Grand Rounds, New Jersey:

HIV Related Lymphomas

2010, Memorial Sloan Kettering Oncology-Hematology Grand Rounds, New

York: Biomarkers in DLBCL: from prognostic significance to molecular function

38

2010, Oncology Grand Rounds, Stanford University. A decade since cloning of

HGAL - clinical significance and molecular function

2009, The 12th International Conference in Differentiation Therapy, Chicago: IL-

21 Cytokine - a Novel Cyto-killer of Diffuse Large B-Cell Lymphoma

2009, The 8th Chinese National Conference on Tumor Metastasis, Tianjin, P.R.

China: HGAL-from Cloning to Function

2009, American Society of Clinical Oncology, Orlando, Florida: Novel Organic

Arsenic Molecule Darinaparsin: Development of IV and Oral Forms

2009, Experimental Malignant Hematology Seminar Series, Moffitt Cancer

Center and Research Institute, Tampa, Florida: Diffuse Large B-cell Lymphoma:

New Insights

2009, The National Cancer Institute’s Integrative Cancer Biology Program (ICBP)

and Tumor Microenvironment Network (TMEN) meeting, Washington DC:

Differentiation Stage Specific Expression of miRNAS in B-lymphocytes and

Diffuse Large B-cell Lymphoma

2009, Ochsner Basic Science in Clinical Medicine Lecture series, Ochsner Clinic

Foundation, New Orleans: Diffuse Large B-cell lymphoma- New Insights

2008, AACR Centennial Conference – Translational Cancer Medicine 2008,

Jerusalem, Israel: Bridging the Lab and the Clinic in Cancer Medicine; Prognostic

Factors in Diffuse Large B-Cell Lymphoma: Present and Future

2008, Lymphoma and Myeloma 2008 meeting, New York: Prognosis in Diffuse

large B cell lymphoma

2008, Stanford University: Diffuse Large B-cell Lymphoma: From Biomarkers to

Novel Mechanisms

2008, 18th Annual Mayo Clinic Hem/Onc Reviews, Amelia Island, Florida:

Prognostic Biomarkers in Diffuse Large B-cell Lymphomas

2008, Cancer Research Center (CIC), Salamanca, Spain: DLBCL- From Gene

Arrays to Gene Function

2008, Translational Science Meeting, Pamplona, Spain: Diffuse Large B-cell

Lymphoma: New Insights

39

2008, Hebrew University Medicine School- invited lecture, Jerusalem; DLBCL -

from gene arrays to gene function

2008, The Israel Association for Bone Marrow Transplantation, Tel Aviv: Genetic

profiling in NHL pre and post Rituximab era – implication for transplantation

2008, ASCO Meeting, Chicago: Clinical Problems in Oncology: Prognosis, Risk

Stratification, and Treatment of Diffuse Large B-Cell Lymphoma: Incorporation of

New Imaging Modalities and Molecular Markers

2008, Hematologic Malignancies Research Meeting, Omaha, Nebraska: Diffuse

Large B-cell Lymphoma: From Biomarkers to Novel Mechanisms and New

Therapies

2008, Cancer Seminar Series, Phoenix, Arizona: DLBCL: From Biomarkers to

Novel Mechanisms and New Therapies

2008, Grand Rounds, Portland, Oregon: Diffuse Large B-cell Lymphoma: From

Biomarkers to Novel Mechanisms and New Therapies

2008, United States and Canadian Academy of Pathology Annual Meeting,

Denver, Colorado: Diffuse Large B-cell Lymphoma: From Biomarkers to Novel

Mechanisms and New Therapies

2008, BMT Tandem Meeting, San Diego, California: Diffuse Large B-cell

Lymphoma: From Gene Expression Profiling to Prediction of Outcome

2007, Emory University Grand Rounds, Atlanta: Diffuse Large B-cell Lymphoma -

From Arrays to Molecular Prognostic Factors and Mechanisms

2007, University of Maryland Greenebaum Cancer Center- Frontiers in Oncology:

Diffuse Large B-cell Lymphoma – From Arrays to Molecular Prognostic Factors

and Novel Mechanisms

2007, ASCO Meeting, Chicago: Prognostic factors in diffuse large B-cell

lymphoma: present and future.

2007 4th International Chicago Lymphoma Symposium: Gene arrays in diffuse

large B-cell lymphoma.

2006, Oncology Congress, New York: Molecular Pathogenesis of Lymphoma.

2006, Joint Cancer Conference of the Florida Universities, West Palm Beach, FL:

Prognostic Biomarkers in Lymphoma.

40

2006, Cleveland Foundation Clinic- Oncology-Hematology Grand Rounds,

Cleveland, Ohio: Diffuse Large B-cell Lymphoma – From Arrays to Molecular

Prognostic Factors and Mechanisms.

2006, Memorial Sloan Kettering Oncology-Hematology Grand Rounds, New

York: Diffuse Large B-cell Lymphoma – From Arrays to Molecular Prognostic

Factors and Mechanisms.

2005, Oncology World Congress, New York: Lymphoma – Clinical and

Molecular Prognostic Models.

2005, American Society of Clinical Oncology, Meet the Professor Session: Bench

to Bedside –Technology in Practice: Gene Arrays in Lymphoma – Changing the

Way We Do Things.

2005, Inaugural Joint American-Israeli Conference on Cancer, Jerusalem:

Diffuse Large B-cell Lymphoma : From Gene Expression Profiling to

Mechanisms.

2004, American Society of Hematology: IL-4 Affects Proliferation,

Chemosensitivity and Rituximab Sensitivity of Germinal Center B-cell like (GCB)

and Activated B-cell like (ABC) Diffuse Large B-cell Lymphoma Differently.

2004, American Society of Hematology: Distinct IL-4 Intracellular Signaling in

Germinal Center B-cell like and Activated B-cell like Diffuse Large B-cell

Lymphoma: Novel Opportunities for Therapeutic Interventions.

2004, OHSU, Portland, Oregon. Medicine Grand Rounds: Diffuse Large B-cell

Lymphoma: from molecular prognostic markers to mechanisms.

2004, Joint Cancer Conference of the Florida Universities, Orlando, Florida,:

Gene expression and fingerprinting in lymphoma.

2003, San Antonio, Texas, Advances in lymphoid malignancies- an expert forum:

Gene arrays in lymphoma.

2003, International Workshop on Lymphoid Malignancies, Palm Beach, FL,:

What clinical studies need to be conducted to validate the use of current and

future prognostic factors in DLBCL?2002, American Society of Hematology: GAL

is a novel IL-4-inducible gene that strongly predicts survival in diffuse large B-cell

lymphoma.

41

2002, Miami, FL, ECOG meeting: DLBCL: new molecular prognostic markers.

2001, American Society of Hematology: Higher-grade transformed follicle center

lymphomas (FCL): Gene expression profiling comparison to pre-transformed FCL

and to de novo diffuse large B-cell lymphomas (DLBCL).

2001, American Society of Hematology: BCL-6 mRNA expression in higher-

grade transformation of Follicle Center lymphoma: Somatic mutations in the first

intron negative regulatory region up-regulate BCL-6 mRNA expression.

2000, American Society of Hematology: Search for ATM gene mutations in

patients with follicle center lymphoma (FCL), in the FCL tumors and in tumors

following transformation to a higher-grade.

2000, American Society of Hematology: BCL-6 proto-oncogene polymorphism

and susceptibility to follicle center lymphoma (FCL).

1999, American Society of Hematology: Molecular analysis of immunoglobulin

genes in diffuse large B-cell lymphomas.

V. Editorial Review and review committees NIH/NCI ZCA1 GRB-P (J1), Discovery, Imaging, and Therapeutics P01 SEP

Review 2011

Stanford Center for Systems Biology (CCSB) – External Advisory Board (EAB)

2011

VELCADE® Advisory Board Meeting 2011

Lymphoma Research Foundation (LRF) Scientific Advisory Board (SAB)

2010, 2011

MD Anderson Cancer Center P01 External Advisory Board (EAB) Targeting

Oncogenic Pathways in Lymphoma Collaboration Meeting 2010

NIH Cancer Biomarkers Study Section (CBSS) – Oncological Sciences

Integrated Grant Review 2009

NCI P01 Clinical SEP Review committee 2006, 2007, 2008, 2009, 2010, 2011

American Cancer Society Extramural Grants-2007

Blood –reviewer

42

Cancer Cell-reviewer

Leukemia – reviewer

Cancer Research – reviewer

Clinical Cancer Research - reviewer

Journal of Clinical Oncology – reviewer

PNAS – reviewer

Cell Reports – reviewer

Nature Medicine - reviewer

Journal of Experimental Medicine – reviewer

Oncogene-reviewer

International Journal of Cancer-reviewer

Leukemia and Lymphoma – reviewer

Haematologica – reviewer

Annals of Hematology - reviewer

ACTA Hematologica – reviewer

American Journal of Hematology - reviewer

Leukemia and Lymphoma Editorial Board

VI. Committees 2003 –present ECOG Lymphoma and Lymphoma Biology Committee

2003-present MD/PhD Program, University of Miami, Miller School of Medicine

2004-2008 Head of the Fellowship training advisory committee - Division of

Hematology-Oncology University of Miami, Miller School of Medicine

2006-present Head of Hematological Site Disease Group, University of Miami,

Miller School of Medicine.

2006- present Director Lymphoma Program

2009- Lymphoma Research Foundation Advisory Board

43

44